Page 65 - Demo

ANALESRANFwww.analesranf.comhttps://clinicaltrials.gov/study/NCT01957956 33. Dartmouth-Hitchcock-Medical-Center. A Phase IIFeasibility Study of Adjuvant Intra-NodalAutologous Dendritic Cell Vaccination forNewly Diagnosed Glioblastoma Multiforme2018 [Available from:https://clinicaltrials.gov/study/NCT00323115.34. Activartis-Biotech. First Line Standard Therapyof Glioblastoma Multiforme With or Withoutadd on Treatment With Trivax, an Antitumour Immune Therapy Based onTumour-lysate Charged Dendritic Cells 2016[Available from:https://clinicaltrials.gov/study/NCT01213407 35. Jonsson-Comprehensive-Cancer-Center. Phase IDose Escalation Study of Autologous TumorLysate-Pulsed Dendritic Cell Immunotherapyfor Malignant Gliomas in Pediatric Patients2020 [Available from:https://clinicaltrials.gov/study/NCT00107185 36. Ahmed N, Brawley V, Hegde M, Bielamowicz K,Kalra M, Landi D, et al. HER2-SpecificChimeric Antigen Receptor-Modified VirusSpecific T Cells for Progressive Glioblastoma:A Phase 1 Dose-Escalation Trial. JAMA Oncol.2017;3(8):1094-101.37. O%u2019Rourke DM NM, Desai A, Melenhorst JJ,Mansfield K, Morrissette JJD, et al. A singledose of peripherally infused EGFRvIIIdirected CAR T cells mediates antigen lossand induces adaptive resistance in patientswith recurrent glioblastoma. Sci Transl Med.2017.38. Administration of HER2 Chimeric AntigenReceptor Expressing CMV-Specific CytotoxicT Cells Ins Patients With GlioblastomaMultiforme (HERT-GBM) 2019 [Availablefrom:https://clinicaltrials.gov/study/NCT0110909539. A Phase I/II Study of the Safety and Feasibilityof Administering T Cells Expressing AntiEGFRvIII Chimeric Antigen Receptor toPatients With Malignant Gliomas ExpressingEGFRvIII 2019 [Available from:https://clinicaltrials.gov/study/NCT0145459640. University-of-Pennsylvania. Phase 1 Study ofEGFRvIII-Directed CAR T Cells Combined WithPD-1 Inhibition in Patients With NewlyDiagnosed, MGMT-UnmethylatedGlioblastoma 2023 [Available from:https://clinicaltrials.gov/study/NCT03726515 Lysate-Pulsed Dendritic Cell Immunotherapyfor Malignant Gliomas 2020 [Available from:https://clinicaltrials.gov/study/NCT00068510 25. Clinica-Universidad-Navarra. Prospective, PhaseII Clinical Trial to Evaluate Efficacy andSafety of Autologous Dendritic CellVaccination in Glioblastoma MultiformePatients After Complete Surgical ResectionWith Fluorescence Microscope 2014[Available from:https://clinicaltrials.gov/study/NCT01006044 26. Precision-Life-Science-Group. ImmunologicalTargeting of CD-133 in RecurrentGlioblastoma: A Multi-center Phase ITranslational and Clinical Study of anAutologous CD-133 DC Vaccine 2018[Available from:https://clinicaltrials.gov/study/NCT0204948927. Phase I/II Trial of Vaccine Therapy With TumorStem Cell Derived mRNA- TransfectedDendritic Cells in Patients ReceivingStandard Therapy for Glioblastoma 2015[Available from:https://clinicaltrials.gov/study/NCT00846456 28. Anti-Tumor Immunotherapy Targeted AgainstCytomegalovirus in Patients With NewlyDiagnosed Glioblastoma Multiforme DuringRecovery From Therapeutic Temozolomideinduced Lymphopenia 2023 [Available from:https://clinicaltrials.gov/study/NCT0063963929. Phase I Trial of Vaccination With AutologousDendritic Cells Pulsed With Lysate DerivedFrom an Allogeneic Glioblastoma Stem-likeCell Line for Patients With Newly Diagnosedor Recurrent Glioblastoma 2021 [Availablefrom: https://clinicaltrials.gov/study/NCT0201060630. A Phase l Trial of Tumor Associated AntigenPulsed Dendritic Cell Immunotherapy forPatients With Brain Stem Glioma andGlioblastoma 2014 [Available from:https://clinicaltrials.gov/study/NCT0057664131. Phase ll Trial of Tumor Lysate-Pulsed DendriticCell Immunotherapy for Patients WithAtypical or Malignant, Primary or MetastaticBrain Tumors of the Central Nervous System2019 [Available from:https://clinicaltrials.gov/study/NCT00576537 32. Mayo-Clinic. Pilot Clinical Trial of AllogeneicTumor Lysate-Pulsed Autologous DendriticCell Vaccination in Newly DiagnosedGlioblastoma 2023 [Available from:Inmunoterapia contra glioblastoma multiformeLuc%u00eda S%u00e1nchez Prieto y %u00c1ngel Cuesta Mart%u00ednez 63 An. R. Acad. Farm.vol. 91. n%u00ba 1 (2025) %u00b7 pp. 45-66